Results from TH-302 clinical trials presented at international lung cancer meeting

August 4, 2009

By hammersmith

[Source: Pipeline] – Threshold Pharmaceuticals, Inc. (Nasdaq:THLD – News) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare today announced clinical trial results related to Threshold’s clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the World Conference on Lung Cancer being held July 31 to August 4, 2009, at the Moscone Convention Center in San Francisco, CA.

For more information: Results From TH-302 Clinical Trials Presented at International Lung Cancer Meeting